Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -1.02 -2.35% 42.40 5,738,974 16:35:17
Bid Price Offer Price High Price Low Price Open Price
42.30 42.53 44.50 41.14 44.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 788.08 218.00 29.80 1.4 309
Last Trade Time Trade Type Trade Size Trade Price Currency
17:42:36 O 58,075 42.04 GBX

Indivior (INDV) Latest News

More Indivior News
Indivior Takeover Rumours

Indivior (INDV) Share Charts

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Intraday Indivior Chart

Intraday Indivior Chart

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
19/7/201921:13INDIVIOR THE PILL WITH NO CHEERS OR BEERS1,704
11/7/201916:13RB. de-merger 542
11/7/201908:29Johnson & Johnson court case oklahoma6
03/5/201910:16Judgement against insys2
31/7/201813:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:42:4542.0458,07524,412.99O
16:31:0842.401,732734.37O
16:04:1542.405,4032,290.76O
15:43:0442.1725,79910,878.15O
15:35:1742.40369,325156,593.80UT
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
19/7/2019
09:20
Indivior Daily Update: Indivior Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 43.42p.
Indivior Plc has a 4 week average price of 39.56p and a 12 week average price of 35.63p.
The 1 year high share price is 353.90p while the 1 year low share price is currently 20.98p.
There are currently 728,306,837 shares in issue and the average daily traded volume is 9,302,157 shares. The market capitalisation of Indivior Plc is £308,802,098.89.
11/7/2019
17:21
waldron: cantrememberthis2 11 Jul '19 - 17:08 - 1442 of 1444 0 0 0 Https://www.evaluate.com/vantage/articles/news/indivior-fights-generic-challenges-threat-litigation-remains-0 Vantage Logo July 11, 2019 Indivior fights off generic challenges but the threat of litigation remains Lisa Urquhart Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance. Today’s 16% rise in Indivior’s share price has less to do with the group selling more of its opioid dependency treatment products than with the inability of its generic competitors to sell theirs. Indivor thrilled the market with substantially upgraded full-year guidance for 2019, as it appeared that generics companies like Dr Reddy's and Mylan had failed to convince patients to try their version of Indivior’s Suboxone film. The product, which has continued to defy conventional wisdom around generic sales erosion, still accounts for the majority of Indivior sales. Another demonstration of Suboxone’s continued grip on the US opioid substitution market is that the product still makes up over 70% of opioid substitution products. This figure includes the 24% of sales contributed by the authorised generic Indivior launched in February as a countermeasure to copycats. Despite the strong showing today Indivior's shares, which have been falling since June 2018 when the FDA approved generic versions of Suboxone film, are still down 55% on the year. Settling for a billion Indivior’s guidance came on the same day that its former parent, Reckitt Benckiser, announced that it had reached an agreement with the Department of Justice and Federal Trade Commission to pay up to $1.4bn to settle claims it had participated in fraudulent marketing schemes to increase sales of Suboxone. As the current owner of Suboxone, Indivior was also named in the investigation. But the UK company has denied the allegations, which it has described as “self-serving” and based on events four years before Indivior was spun out of Reckitt in 2014. Reckitt’s $1.4bn settlement is one of the biggest the industry has seen, though it is still eclipsed by Glaxosmithkline’s eye-watering $3bn payout for failing to disclose safety information around diabetes drug Avandia. Read-through? While it might not be pharma’s largest payout, $1.4bn is still a large amount of money even if the compay on the hook for it has a market cap of £47bn. And here is the rub for Indivior, which for litigation purposes has far shallower pockets than Reckitt. So far Indivior, which only has a market cap of £389m ($480m), has set aside $438m for any form of payout. Indivior has also chosen to go to trial to refute the DoJ/FTC allegations. A hearing is not expected until 2020 and could take up to two years to conclude, meaning any overhang to Indivior shares could continue for another three years. But what today’s announcement by Reckitt shows is that it is possible to settle with the DoJ without any requirement to admit wrongdoing. This non-prosecution type agreement is important if Indivior wants to retain its current access to US government Medicare and Medicaid contracts, which currently represent around half of its US business. As to the size of any settlement for which Indivior might be liable, some analysts are not expecting the amount forked out by Reckitt, which would effectively bankrupt Indivior. “The DoJ knows that they are not going to get $1.5bn out of Indivior, but they might get a bit more than what Indivior has set aside. If they can get $600m or $700m and settle then everyone can move on,” said one healthcare analyst. Until then, despite its success in holding off the more immediate generic threats, Indivior will still remain a tricky investment case.
11/7/2019
17:15
waldron: Now for a bit of fun by using the past to perhaps predict the future by way of boxes 40 to 50p$$$$$$$$$$$ WE ARE STILL HERE$$$$$$$$$$$$$$$$$ 50 to 60p 60 to 70p$$$$$$$$$$$ WE WERE HERE$$$$$$$$$$$$$$$$$ 70 to 80p 80 to 90pXMAS 2019 90 to 100p 100 to 110p XMAS 2020 110 to 120p 120 to 130pXMAS 2021 First hurdle will be results at july end SHARE PRICE suggestions appreciated TOGETHER WITH SENSIBLE TIME FRAMES CERTAINLY WILL UPDATE IF TIMETABLE AHEAD OF SCHEDULE TO BE CONTINUED WITH POSSIBLE EXTRA COMMENT AND UPDATED ON A MONTHLY BASIS Https://www.marketscreener.com/INDIVIOR-19344116/ The intial push was on the 11th july 2019 from 44.30p with a high during the day of 62.76p eventually closing down again to 47.28p Http://uk.stoxline.com/q_uk.php?s=indv
11/7/2019
11:33
steeplejack: From FTAlphaville.They217;ve included a Jeffries comment too but that was posted earlier.I think this sums things up best.Indivior is not off the hook.The primary reason the shares are up is due to raised guidance. STIFEL ........ Indivior has upgraded its guidance for FY19, on the back of continued slower-thanexpected generic erosion of its Suboxone film product in the US. Indivior now expects full-year revenues of $670m-$720m (previously $525m-$575m) and net income at $80m-$130m (previously -$40m to $10m). Sublocade revenue guidance of $50-$70m is unchanged. By coincidence, Reckitt Benckiser (RB) has announced a settlement with the DoJ and FTC for $1.4bn to resolve the long-running investigation into its role in the sales and marketing of Suboxone film. Importantly, the settlement has not required any admission of wrongdoing and will not impact RB's participation in all US government funded programmes. While the RB case is completely separate to Indivior's, it does indicate that a settlement, without admission of wrongdoing and the consequent implications, can be reached with the DoJ. Indivior continues to be willing to fight the DoJ in court, but is also in parallel talking to the US Department of Health and Human Services (HHS) to find a way to avoid being excluded from government contracts. The DoJ court case is due to start in May 2020. While there remains significant uncertainty about the eventual outcome of litigation with DoJ, we believe this is fully reflected in the share price. We therefore retain our Hold recommendation, but upgrade our target price to 60p (previously 44p) on the back of the revised guidance and higher cash balance (now $985m).
11/7/2019
10:51
waldron: tariq_khan 11 Jul '19 - 10:46 - 1381 of 1382(premium) 0 1 0 Does this mean that INDV has to cough up money to pay some of the 1.4 billion fine, lionheart69uk1 11 Jul '19 - 10:48 - 1382 of 1382 0 1 0 Is there any chance that Indivior came to some negotiated settlement with Reckitt as otherwise why has the share price not shot up to over 100p? SENSIBLE QUESTIONS AND MIGHT WELL BE THE CASE AS TSMITH HAS MENTIONED tsmith2 11 Jul '19 - 10:36 - 1378 of 1378 0 2 0 When Indivior became a separate entity, the two companies agreed on a so-called mutual indemnity clause, under which Indivior would reimburse Reckitt for any liability imposed on the company for matters relating to its business, and vice versa.
11/7/2019
08:57
steeplejack: Net income guidance has been more than doubled on a hike of around 30% in revenue guidance implying much better than anticipated margins.The current rise in share price seems more than justified on the increased forecast alone.Once the settlement is digested,the shares should climb back towards a pound.
04/7/2019
15:21
sarkasm: jonsols 4 Jul '19 - 07:34 - 1284 of 1285 0 0 0 Hmmm. Share price is based on future earnings. Regardless of whether INDV has or as not made provision in the books the share price includes a discount for the risk of adverse outcome. Single question for me is whether the market has under or over cooked the discount relative to the most likely outcome at this stage. Not an easy one to adjudge without intimate inside knowledge I would think... mwainw1973 4 Jul '19 - 14:37 - 1285 of 1285 0 0 0 So share price is not influenced by results? LOL In my opinion the share price is influenced by all things depending on the day Results,charts,news broker recommendation, trumptweets and the full moon not so much by whats posted here it being an illiquide share perhaps even the market makers hold sway
04/7/2019
07:34
jonsols: Hmmm. Share price is based on future earnings. Regardless of whether INDV has or as not made provision in the books the share price includes a discount for the risk of adverse outcome. Single question for me is whether the market has under or over cooked the discount relative to the most likely outcome at this stage. Not an easy one to adjudge without intimate inside knowledge I would think...
17/4/2019
21:22
floridamassive: One thing I don’t understand is after the standard life RNS came out, rather than going up, why the hell share price dropped by 4%?? Surely, it’s a good thing that they increased their stake in INDV!? Doesn’t make any sense? What am I missing here? share price has been behaving very strangely today.
10/4/2019
10:40
rzbrdbe: Indv has always been un-investible because of the litigation hanging over it. Investors have only themselves to blame for not reading Indivior's accounts. The company has been very clear about the possibility of an adverse judgement in note 20 of its latest 2018 accounts (see below). It has carried a provision of $438m for many years, being its estimated costs of any resultant litigation (costs to be shared with Reckitt who have set aside a similar amount), but the political climate has now changed. Yes, you could argue that the 3bn sought by the DOJ is over egged but if 3bn is the outcome then the statement in note 20 of the accounts will become fact: "the Group would not continue in business without taking further necessary measures to reduce its cost base and improve its cash flow" and shareholders equity would be wiped out. Shame, because the company appears to have been doing the right thing since separating from Reckitt by developing the implantable sublocade product, possibly a viable new addition to a solution for the US opioid crisis. Reckitt's management clearly saw this issue too hot to handle in 2014 (they are still on the hook for half, hence the decline of 10% in share price). Indv is still un-investible Note 20: "The Group carries a provision for investigative and antitrust litigation matters of $438m. Substantially all of the provision relates to the U.S. Department of Justice investigation. The Group is in advanced discussions with the Department of Justice about a possible resolution to its investigations, although it cannot predict with any certainty whether, when, or at what cost it will reach an ultimate resolution. Although the total amount of the provision has not changed, the classification between current and non-current has changed due to a shift in management’s best estimate of the timing of payments. In the event the final settlement amount of the DOJ matter is materially higher than the provision or is required to be paid over a shorter period of time, and the Group is further adversely impacted by higher than expected loss of revenue following the ‘at-risk’; launch of generic buprenorphine/naloxone sublingual film products or the failure for new products to meet revenue growth expectations, the Group would not continue in business without taking further necessary measures to reduce its cost base and improve its cash flow"
21/11/2018
08:05
pwhite73: PWhite731 Oct '18 - 22:32 - 452 of 491 Edit 0 0 0 The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here. 1. The opioid addiction market is too competitive and relatively easy to enter. 2. The injunction against Dr Reddy is only temporary. 3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US. The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again
Indivior share price data is direct from the London Stock Exchange
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190719 21:33:31